Master FIH clinical trials in Cuba with key insights on regulatory pathways and execution strategies.
Introduction First-in-Human (FIH) clinical trials in Cuba offer a pivotal opportunity for MedTech and Biopharma innovators, yet they come with significant regulatory hurdles that must be navigated carefully. These trials are essential for assessing the safety and efficacy of new treatments, laying the groundwork for future research phases. Navigating the intricate regulatory landscape can hinder timely approvals, posing a significant challenge for innovators. What strategies can stakeholders adopt to tap into local expertise and forge partnerships that enhance their FIH trial success? By leveraging local knowledge and strategic collaborations, stakeholders can streamline their FIH trial processes and maximize their chances of success in this evolving environment. Define First-in-Human Clinical Trials First-in-Human (FIH) clinical studies represent a critical juncture in the journey of new drugs and medical devices, transitioning from preclinical research to human evaluation. These ass…